卵子が精子の減数分裂を肩代わりする~減数分裂を進行させ、子まで発生させられることを発見~

ad

2025-11-28 理化学研究所

理化学研究所らの国際共同研究グループは、減数分裂が途中で停止した雄性生殖細胞(一次精母細胞)を卵子に顕微授精すると、卵子側の減数分裂機構が「肩代わり」して減数分裂を完了させ、産子まで発生し得ることをマウスで示した。さまざまな無精子症モデルマウス9系統を用いて、一次精母細胞のどの発生ステージならば卵子内で減数分裂を再開できるかを検証した結果、ディプロテン期まで正常に進んでいる場合には、顕微授精後に減数分裂が進行し、合計28匹の正常な産子とその子孫が得られた。一方、より前段階のパキテン期で停止している場合や、ディプロテン期に異常がある場合には、胚発生や着床が成立しなかった。これらの結果から、減数分裂停止による男性不妊の一部では、減数分裂直前まで成熟した一次精母細胞を用いれば、将来的に新たな生殖補助医療につながる可能性が示唆された。

卵子が精子の減数分裂を肩代わりする~減数分裂を進行させ、子まで発生させられることを発見~
一次精母細胞顕微授精における雄性生殖細胞発生ステージと産子作出能の関係

<関連情報>

無精子症変異マウスにおいて、減数分裂卵母細胞への精母細胞注入は複糸期停止を救済するが、パキテン期停止は救済しない Spermatocyte injection into meiotic oocytes rescues diplotene, but not pachytene, arrest in azoospermic mutant mice

Narumi Ogonuki, Toshiaki Hino, Yasuhiro Fujiwara, Yuki Osawa, Seiya Mizuno, Fumihiro Sugiyama, Tetsuo Kunieda, Junko Otsuki, Seiya Oura, Tamio Furuse …
Human Reproduction Open  Published:22 October 2025
DOI:https://doi.org/10.1093/hropen/hoaf067

Abstract

STUDY QUESTION

At which arrest stage can spermatocytes be rescued by injection into meiotic oocytes?

SUMMARY ANSWER

In mice, spermatocytes arrested at the diplotene stage, but not at the pachytene stage, can resume meiosis within immature oocytes and support full-term embryonic development.

WHAT IS KNOWN ALREADY

In mice, at least some of the spermatocyte arrest mutations can be overcome by injecting spermatocytes into immature oocytes.

STUDY DESIGN, SIZE, DURATION

The study was carried out from October 2019 to April 2025. Adult azoospermic mice (at 4–26 weeks of age) from nine strains carrying spermatocyte arrest mutations were used as spermatocyte donors. Adult B6D2F1 females at 9–12 weeks of age were used as oocyte donors for spermatocyte injection. Adult ICR strain pseudopregnant females at 9–12 weeks of age were used as recipients for embryo transfer experiments.

PARTICIPANTS/MATERIALS, SETTING, METHODS

The most advanced stage of spermatocytes from each mutant strain was assessed by chromosome spread analysis. These most advanced spermatocytes of each strain were injected into metaphase I (MI) oocytes. About half a volume of the ooplasm had been removed from the recipient oocytes to ensure more stable chromosome behaviours during meiosis. The spermatocyte-injected oocytes were allowed to mature in vitro to the metaphase II (MII) stage, and their ooplasm was refreshed with the ooplasm from intact MII oocytes. After activation with SrCl2, the reconstructed oocytes that reached the 2-cell stage were transferred into the oviducts of pseudopregnant females. On Day 19.5, recipient females were euthanized and their uteri were examined for live foetuses.

MAIN RESULTS AND THE ROLE OF CHANCE

Based on spermatocyte spread analysis, sperm mutants were categorized into three classes: Class 1, arrest at mid-diplotene or later stage; Class 2, arrest at early diplotene stage; and Class 3, arrest at pachytene stage. All four Class 1 mutants could resume normal meiosis following injection into MI oocytes, as evidenced by births of normal offspring. Similarly, one of two Class 2 mutants could be rescued, but the other could not. By contrast, three Class 3 mutants did not support embryo development to term because of complete implantation failure, indicating that reconstructed embryos carried severe chromosomal aberrations.

LARGE-SCALE DATA

N/A.

LIMITATIONS, REASONS FOR CAUTION

The number of mutant strains examined was limited. Nevertheless, the findings were consistent: the more advanced the arrest stage of spermatocytes, the higher the likelihood of a successful rescue.

WIDER IMPLICATIONS OF THE FINDINGS

In humans, a considerable proportion of spermatogenic arrest occurs at the primary spermatocyte stage. Spermatocyte injection might be an option to treat human male-factor infertility due to azoospermia in the future. However, numerous ethical and technical challenges remain to be addressed, and the reproductive physiological differences between mice and humans must be carefully taken into account.

STUDY FUNDING/COMPETING INTEREST(S)

This study was supported by Grants-in-Aid for Scientific Research (KAKENHI) from the Japan Society for the Promotion of Science to A.O. (grant number: JP19H05758), K.I. (grant number: 23H04956), M.I. (grant number: JP23K20043), and N.O. (grant number: 25H01372), and 2023 and 2025 grants of the University of Castilla-La Mancha for stays in foreign universities and research centres to E.C.-E. The authors declare that they have no conflicts of interest.

細胞遺伝子工学
ad
ad
Follow
ad
タイトルとURLをコピーしました